FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 675 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in... August 19, 2025 Man Who Lost His Leg Teaches Martial Arts To Orphans Of... December 7, 2021 Take a Small Step April 21, 2021 Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... September 16, 2024 Load more HOT NEWS Efficacy and Safety of Futibatinib in Patients with Previously Treated Intrahepatic... Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer... Our 10 top tips to help you talk about cancer The Appraisal – Scientific disruption: what is it, and do we...
